We are live on ! Find out more
RAPT

RAPT Therapeutics
RAPT

Delisted

RAPT was delisted on the 2nd of March, 2026.

Back to rankings

106 hedge funds and large institutions have $611M invested in RAPT Therapeutics in 2023 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 35 increasing their positions, 28 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,548% more call options, than puts

Call options by funds: $10.9M | Put options by funds: $664K

80% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 15

25% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 28

12% more funds holding

Funds holding: 95 → 106 (+11)

0.34% more ownership

Funds ownership: 11.8% → 12.14% (+0.34%)

3% less capital invested

Capital invested by funds: $626M → $611M (-$15.7M)

17% less funds holding in top 10

Funds holding in top 10: 6 → 5 (-1)

Holders
106
Holders Change
+11
Holders Change %
+11.58%
% of All Funds
1.69%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.08%
New
27
Increased
35
Reduced
28
Closed
15
Calls
$10.9M
Puts
$664K
Net Calls
+$10.3M
Net Calls Change
-$4.13M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$38M
2
CAM
Cormorant Asset Management
Massachusetts
+$16.4M
3
PA
Perceptive Advisors
New York
+$12.5M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$8.23M
5
PAMP
Polar Asset Management Partners
Ontario, Canada
+$7.99M

Top Sellers

Rank Fund Capital Flow
1
B
Braidwell
Connecticut
-$19.8M
2
DTC
Deep Track Capital
Connecticut
-$18.5M
3
State Street
State Street
Massachusetts
-$7.63M
4
Walleye Capital
Walleye Capital
New York
-$6.26M
5
SSA
Schonfeld Strategic Advisors
New York
-$5.58M
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$5.26M +$895K +4,423 +14%
FAM
27
Fred Alger Management
New York
$3.61M +$4.81M +23,790 +3,086%
Charles Schwab
28
Charles Schwab
California
$3.58M +$601K +2,973 +14%
SC
29
Samlyn Capital
New York
$3.42M +$4.71M +23,283 New
Goldman Sachs
30
Goldman Sachs
New York
$3.19M -$602K -2,977 -12%
Bank of America
31
Bank of America
North Carolina
$2.55M -$99.7K -493 -3%
Two Sigma Advisers
32
Two Sigma Advisers
New York
$2.18M -$465K -2,300 -13%
Rafferty Asset Management
33
Rafferty Asset Management
New York
$2.04M -$878K -4,341 -24%
Citigroup
34
Citigroup
New York
$2.04M +$635K +3,139 +29%
Renaissance Technologies
35
Renaissance Technologies
New York
$1.99M +$1.93M +9,525 +236%
Citadel Advisors
36
Citadel Advisors
Florida
$1.88M +$863K +4,266 +50%
Balyasny Asset Management
37
Balyasny Asset Management
Illinois
$1.86M +$2.56M +12,658 New
Qube Research & Technologies (QRT)
38
Qube Research & Technologies (QRT)
United Kingdom
$1.83M +$2.52M +12,451 New
Norges Bank
39
Norges Bank
Norway
$1.8M -$4.05M -20,012 -62%
D.E. Shaw & Co
40
D.E. Shaw & Co
New York
$1.76M -$775K -3,830 -24%
TD Asset Management
41
TD Asset Management
Ontario, Canada
$1.72M – – –
Bank of New York Mellon
42
Bank of New York Mellon
New York
$1.71M +$266K +1,315 +13%
UOC
43
UBS O'Connor
Illinois
$1.69M +$2.33M +11,506 New
Los Angeles Capital Management
44
Los Angeles Capital Management
California
$1.68M -$752K -3,716 -25%
TOCUITCONY
45
Trustees of Columbia University in the City of New York
New York
$1.48M +$182K +900 +10%
AG
46
Algert Global
California
$1.36M +$134K +662 +8%
Millennium Management
47
Millennium Management
New York
$1.27M +$374K +1,851 +27%
Two Sigma Investments
48
Two Sigma Investments
New York
$1.17M +$1.09M +5,395 +210%
Swiss National Bank
49
Swiss National Bank
Switzerland
$1.14M -$174K -862 -10%
Manulife (Manufacturers Life Insurance)
50
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.13M – – –
1
2
3 4 5

RAPT Hedge Fund Activity: Q1 2023 in Review

106 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q1 2023, worth a combined $611M — down 2.5% from $626M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new RAPT positions and 15 closed out — a net gain of 12 holders — while 35 added to existing stakes and 28 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $38M. The largest seller was Braidwell, exiting entirely with an estimated $19.8M sold.

  • 106 institutional investors held RAPT Therapeutics (RAPT) as of Q1 2023, up from 95 in Q4 2022.
  • Funds reported $611M of RAPT Therapeutics stock for Q1 2023, down 2.5% quarter-over-quarter.
  • 27 funds opened new RAPT Therapeutics positions in Q1 2023 and 15 closed out, a net change of +12 holders.
  • The largest RAPT Therapeutics buyer in Q1 2023 was Fidelity Investments, an estimated $38M added.
  • The largest RAPT Therapeutics seller in Q1 2023 was Braidwell, an estimated $19.8M sold.

Based on aggregated 13F filings for Q1 2023.